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The proliferative pool and regenerative potential of neural stem cells diminishes with age,
a phenomenon that may be exacerbated in prodromal and mild Alzheimer’s disease (AD)
brains. In parallel, the neuroactive progesterone metabolite, allopregnanolone (APα), along
with a host of other factors, is decreased in the AD brain. Results of preclinical analyses
demonstrate that APα is a potent inducer of neural progenitor proliferation of both rodent
and human derived neural progenitor cells in vitro. In vivo, APα signiﬁcantly increased neu-
rogenesis within the subgranular zone of the dentate gyrus and subventricular zone of
the 3xTgAD mouse model. Functionally, APα reversed the learning and memory deﬁcits
of 3xTgAD mice prior to and following the onset of AD pathology and was comparably
efﬁcacious in aged normal mice. In addition to inducing regenerative responses in mouse
models of AD, APα signiﬁcantly reduced beta-amyloid burden, beta-amyloid binding alcohol
dehydrogenase load, and microglial activation. In parallel, APα increased markers of white
matter generation and cholesterol homeostasis. Analyses to determine the optimal treat-
ment regimen in the 3xTgAD mouse brain indicated that a treatment regimen of APα once
per week was optimal for both inducing neurogenesis and reducing AD pathology. Pharma-
cokinetic analyses indicated that APα is rapidly increased in both plasma and brain following
a single dose. APα is most efﬁcacious when administered once per week which will con-
tribute to its margin of safety. Further, analyses in both animals and humans have provided
parameters for safe APα dosage exposure in humans. From a translational perspective,
APα is a small molecular weight, blood brain barrier penetrant molecule with substantial
preclinical efﬁcacy data as a potential Alzheimer’s therapeutic with existing safety data in
animals and humans.To our knowledge, APα is the only small molecule that both promotes
neural progenitor regeneration in brain and simultaneously reduces AD pathology burden.
Keywords: allopregnanolone,Alzheimer’s disease, β-amyloid, neurogenesis, regeneration, cholesterol homeostasis,
myelin, treatment regimen
INTRODUCTION
Dynamic neural stem-cell proliferation zones apparent in the
developing central nervous system are also present in the adult
brain, primarily restricted to the dentate gyrus subgranular zone
(SGZ; Altman and Das, 1965; Cameron et al., 1993; reviewed in
Liu and Brinton, 2010) of the hippocampus and the subventricu-
lar zone (SVZ) of the lateral ventricle (Altman, 1969; Luskin, 1993;
reviewed in Liu and Brinton, 2010). These regions retain regen-
erative potential throughout the life span with marked declines
in aged brain (Kuhn et al., 1996; Cameron and McKay, 1999;
reviewed in Liu and Brinton, 2010). Adult mammalian neuro-
genesis has been conﬁrmed in humans (Eriksson et al., 1998).
Quantitatively a remarkable degree of neurogenesis occurs in the
rat dentate gyrus on a daily basis with 9,400 cells proliferating
with a cell cycle time of 25 h (Cameron and McKay, 2001). By
this estimate, ∼9,000 new cells would be generated in the den-
tate gyrus each day or more than 250,000 per month. Within
1–2weeks of 5-bromo-2′-deoxyuridine (BrdU) injection, 50–60%
of all BrdU-labeled (BrdU+) cells in the dentate gyrus express
neuron-speciﬁc markers. The number of new granule neurons
generated each month is 6% of the total size of the granule cell
population and 30–60% of the size of the afferent and efferent
populations. Although most newborn granule cells do not survive,
3% of these cells are replaced every month which corresponds
to ∼0.1% per day in young adult mice and rats (Kempermann
et al., 1997; Cameron and McKay, 1999; Liu and Brinton, 2010).
In the rat dentate gyrus, 85% of the granule cells are formed post-
natally (Bayer and Altman, 1974). Immature granule cells reach
their highest level within the second postnatal week, while mature
granule cells reach asymptotic levels at 2months of age (Bayer
and Altman, 1974). Proliferation of granule cell precursors is age-
associated and proliferation of these cells declines with increased
age (Kuhn et al., 1996). A decline in granule cell proliferation
correlated with high levels of corticosteroids that decreased neu-
rogenic potential (Cameron and McKay, 2001). The rat SVZ is
estimated to produce 30,000 neuroblasts per day (Alvarez-Buylla
et al., 2000). Together with the 9,000 new granule cells, roughly
40,000 new cells are available to regenerate the adult rat brain
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every day. Relative to juvenile rats, year-old rats displayed a 94%
reduction in neurogenesis due to a 92% drop in cell production
(McDonald and Wojtowicz, 2005). Aging alone does not overtly
weaken the intrinsic neuronal properties of newborn granule cells.
In the aged rodent, the relatively few new neurons that survive
in the dentate gyrus develop typical granule cell morphology
and spine density (Morgenstern et al., 2008). Surviving neurons
possess a synaptic density of afferent glutamatergic connections
comparable to that of neurons born in young adults (Morgen-
stern et al., 2008). Decreased neurogenesis has been proposed
as a factor in the age-related decline of cognitive ability (Bizon
and Gallagher, 2003; Drapeau et al., 2003; Kempermann et al.,
2004).
Newborn granule cells arise from the hippocampal SGZ within
the dentate gyrus and functionally integrate into the preexisting
neural circuitry (van Praag et al., 2002) to inﬂuence hippocampal-
dependent processes including spatial pattern recognition (Clel-
land et al., 2009). Experimental methods that inﬂuence neuro-
genesis include exercise (van Praag et al., 1999, 2002; Pereira
et al., 2007; Rodriguez et al., 2011), environmental enrichment
(Thuret et al., 2009; Rodriguez et al., 2011), deep brain stimula-
tion (Toda et al., 2008; Encinas et al., 2011; Stone et al., 2011),
stem-cell transplantation (Blurton-Jones et al., 2009), and phar-
macologic intervention by peptide growth factor delivery (Massa
et al., 2010) or small molecules (Malberg et al., 2000; Mayo et al.,
2005; Wang et al., 2005; Taupin, 2009; Pieper et al., 2010). Gluta-
matergic and cholinergic synaptic input from the surrounding
hippocampal circuitry penetrate the SGZ of the adult dentate
gyrus. However, the local microenvironment of the adult den-
tate gyrus SGZ retains an embryonic-like state wherein nearly
exclusive gamma-aminobutyric acid type A receptor (GABAAR)
chloride channel depolarizing inputs surround progenitors in the
neurogenic niche (Tozuka et al., 2005). While GABA is typi-
cally an inhibitory neurotransmitter, GABA is excitatory to neural
progenitor cells and triggers an efﬂux of chloride to modu-
late a cascade of molecular events that regulate cell prolifera-
tion (Figure 1). Adult-generated granule cells initially receive
GABAergic input from local interneurons, isolated from extrin-
sic excitatory input (Overstreet Wadiche et al., 2005). Adult-
generated granule cells mature at a slow rate in comparison to
the perinatal granule cells which are exposed to the hyperprolifer-
ative environment required for brain development. Nevertheless,
GABAAR excitation initiates a cascade of events leading to cal-
cium inﬂux in adult neuroprogenitor cells subsequently inducing
the accumulation of a neurogenic transcription factor, NeuroD
(Tozuka et al., 2005). Work by Hisatsune’s group found signiﬁ-
cant inward currents in Type-2 cells but not Type-1 cells following
GABA exposure (Tozuka et al., 2005). In response to depolar-
ization events, transcription factor-activated processes promote
mitosis, and subsequent granule cell maturation (Overstreet-
Wadiche et al., 2006) that occurs in the weeks following cell
division.
Neurosteroids bind to GABAAR at sites that differ from GABA,
benzodiazepines, ethanol, andbarbiturate binding sites and can act
as positive or negativemodulators of GABAAR function (Gee et al.,
1987, 1988; reviewed in Liu and Brinton, 2010). Allopregnanolone
(APα; 3α-hydroxy-5α-pregnan-20-one; also known as AP, Allo, or
THP) is a potent positive allosteric activator of the GABAAR chan-
nels which at nanomolar concentrations enhances the action of
GABA at GABAAR and at higher concentrations directly activates
GABAAR.APαbinds to two transmembrane sites of theheteropen-
tameric GABAAR (Hosie et al., 2006). GABA and neurosteroid
transmembrane binding sites each occur twice per channel com-
plex. The binding sites are conserved throughout all GABAAR
subtypes with the general subunit stoichiometry 2α:2β:1γ with
the γ subunit replaced by the neurosteroid-sensitive δ subunit in
some extrasynaptic channel complexes. The αβγ and αβδ recep-
tor composites are pharmacologically distinct. GABA plays a key
role in generation of the spontaneous network activity of imma-
ture dentate granule cells (Owens and Kriegstein, 2002; Sipila
et al., 2004). In neuroprogenitor cells, GABAergic depolarization
of the uniquely reversedmembrane potential underlies the trophic
actions of APα (Figure 1). Adult dentate granule cells, devoid of
the α1 subunit, are also subjected to tonic GABAergic signaling via
δ subunit containingGABAARsmediated by surrounding synaptic
boutons of local interneurons (Overstreet Wadiche et al., 2005).
GABAARs have been observed by electron microscopy at mem-
brane sites on BrdU co-labeled adult hippocampal SGZprogenitor
cells (Mayo et al., 2005). APα-potentiated GABAergic stimulation
of neural progenitor cells elicits an efﬂux of chloride and a con-
comitant inﬂux of calcium that contributes to the induction of
cell signaling events leading to gene transcription of mitotic genes
and downregulation of anti-mitotic genes (Figure 1). GABAergic
signaling in the SVZ also controls proliferation of adult prog-
enitor cells within the neurogenic niche (Liu et al., 2005). The
survival and maturation potential of newborn neural cells as evi-
denced through enhanced learning and memory (Figure 2; Wang
et al., 2010; Singh et al., 2011) is achieved through modulation of
GABAergic signaling with optimal pulses of APα (Figure 3; Chen
et al., 2011).
Enzymatic conversion of progesterone to its metabolites
occurs in the brain and periphery. Neurosteroids are synthe-
sized in the central and peripheral nervous system, particu-
larly in myelinating glial cells, astrocytes, and several neuronal
cell types. A region-speciﬁc expression pattern of progesterone
converting enzymes is evident in both hippocampus and cor-
tex. In steroidogenic cells, biosynthesis of neuroactive steroids
is controlled by the 18-kDa outer mitochondrial membrane
translocator protein (TSPO; Rupprecht et al., 2010) and TSPO-
associated proteins including the steroidogenic acute regula-
tory protein (StAR) to form a macromolecular signaling com-
plex which transports cholesterol through the mitochondrial
inner membrane to the mitochondrial matrix to be converted
into pregnenolone by the cytochrome P450 side-chain cleavage
(CYP450scc) enzyme (Liu et al., 2006). Pregnenolone subse-
quently diffuses back into the cytoplasm whereby its conversion
to progesterone is facilitated by the 3β-hydroxysteroid dehydro-
genase (3β-HSD) enzyme. APα is synthesized in the brain from
progesterone by the sequential action of 5α-reductase (5α-R)
type-I and 3α-hydroxysteroid dehydrogenase (3α-HSD; Mellon
et al., 2001; Mellon, 2007). The rate-limiting step is the unidi-
rectional reduction of progesterone to 5α-dihydroprogesterone
by 5α-R. Subsequently, 3α-HSD catalyzes conversion of 5α-
dihydroprogesterone into APα. Interestingly, 5α-R and 3α-HSD
Frontiers in Endocrinology | Neuroendocrine Science January 2012 | Volume 2 | Article 117 | 2
Irwin et al. Endogenous regenerative therapy for Alzheimer’s disease
FIGURE 1 | Allopregnanolone (APα) mechanism of action promotes
neurogenesis. (1) APα activates the GABA type A receptor to initiate the
efﬂux of chloride ions (Cl−) from neural progenitor and neural stem cells. (2)
Extrusion of Cl− from the intracellular compartment leads to membrane
depolarization and activation of the voltage dependent L-type calcium channel.
(3) The intracellular calcium (Ca++) rise activates Ca++dependent kinases that
ultimately lead to regulation of gene expression and protein synthesis of cell
cycle proteins. (4) Involving the transcription factor cyclic AMP response
element binding protein (CREB) signaling pathway, APα up-regulates the
expression of cell cycle genes that promote neural progenitor mitosis while
simultaneously down regulating genes that repress cell division. (5) The
mechanism of APα-induced neurogenesis takes advantage of the
developmentally regulated direction of Cl− ﬂux to induce neurogenesis in
those cells that are phenotypically competent to divide while not activating
those mechanisms in mature neurons (Wang et al., 2005; Brinton andWang,
2006). Adult hippocampal neural progenitor cells (BrdU+ cells immunolabeled
green; NeuN+ cells are colored red; coronal section of mouse hippocampal
dentate gyrus; scale bar=50μm) in the image above are shown as an
illustrative example of neurogenesis within the mouse dentate gyrus
subgranular zone (SGZ). Newly born granule cells proliferate and develop into
neurons and glia along the border between the hilus and the granule cell layer.
Migration (through the vertical space of the granule cell layer (GCL); arrows
indicate sequence of temporal development) and integration of these cells
occurs within the days and weeks following proliferation. Newly born neurons
that survive will continue to mature and send axonal projections to form
mossy ﬁber synapses in the CA3 subﬁeld and dendrites to extend into the
molecular cell layer (MCL) to receive glutamatergic afferents from the
perforant pathway of the entorhinal cortex.
are functionally expressed in pluripotent progenitor cells (Mel-
cangi et al., 1996).
APα and other trophic factors are diminished in the brains
of Alzheimer’s disease (AD) patients compared to age-matched
controls (Weill-Engerer et al., 2002; Marx et al., 2006; Naylor
et al., 2010). An early feature of AD is the loss of episodic and
semantic memory (Perry et al., 2000). AD diagnostic imaging
studies using volumetric MRI reveal a decreased hippocampal
volume due to atrophy of gray matter, i.e., neurodegeneration
in amnestic subtype mild cognitive impairment in the progres-
sion toAD (Whitwell et al., 2007). Neuropathological hallmarks of
AD include extracellular and intracellular deposition of β-amyloid
(Aβ) protein, neuroﬁbrillary tangles and neurodegeneration. AD
causes extensive neurodegeneration to the cholinergic neurons of
the nucleus basalis and to a greater extent to the noradrenergic
neurons of the locus coeruleus (Zarow et al., 2003). In addition to
the usual culprits that lead to neurodegeneration, it was discov-
ered that a subpopulation of dysfunctional neurons in AD display
aberrant entry into the cell cycle and replicate their genomes but
fail to divide leading to a fatal apoptotic mechanism (Busser et al.,
1998; Herrup, 2010). There have been no neurogenic therapies
developed to prevent neurodegenerative mechanisms of aberrant
cell cycle entry. The fundamental role of neurogenesis in AD eti-
ology is not without controversy. Several studies have reported
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decreased neurogenesis in AD mouse models (Lazarov and Marr,
2010). However, there are few human studies to conﬁrm or reject
the importance of neurogenesis in AD. Controversial ﬁndings
by Jin et al. (2004) showed increased expression of doublecortin
(DCX), a marker for new neurons, in a cohort of senile patients
and suggested that neurogenesis is increased as a compensatory
mechanism of neurodegeneration. The report by Boekhoorn et al.
(2006) challenged the ﬁndings reported by Jin et al. and demon-
strated that in humanpresenileADbrain,most of the proliferation
could be accounted for by glial and vasculature-associated changes
and found no evidence for altered neurogenesis in the dentate
gyrus. Thus, in AD brain, the extent of neural proliferation and its
potential for regenerative therapeutic responsiveness remains an
active area of investigation.
PRECLINICAL DISCOVERY OF ALLOPREGNANOLONE AS A
PRO-NEUROGENIC AGENT IN VITRO
Our discovery investigations of APα effects in immature hip-
pocampal cells began nearly two decades ago beginning in vitro
then advancing to in vivo studies, all reviewed herein (Brinton,
1994). It was known that seizure activity was associated with
aberrant hippocampal nerve cell growth and that APα protected
against seizure activity (Brinton, 1994). What was not known
at the time was whether APα prevented against aberrant cir-
cuit development. Our initial attempts to address this question
were in vitro analyses using videomicroscopy of hippocampal
neurons in culture to determine the impact of APα on neurite
outgrowth in real time (Brinton, 1994). Results of these analy-
ses revealed that APα induced a signiﬁcant decrease in the area
and length of neurites within 40min of exposure. A concomi-
tant decrement in the number and length of ﬁlopodia decorating
neuritic extensions also occurred within the same time frame. An
unforeseen outcome was the observation that within APα-treated
neurons, retrograde transport of intracellular organelles occurred.
APα-induced regression of neuronal morphology and retrograde
transport of organelles was only observed in hippocampal cells
that had not yet established contact with other neuronal or glial
cells in culture. Established structural connections between neu-
rons or glia did not regress during APα exposure. The cellular
selectivity for the morphological effect of APα was an early indi-
cator of a more signiﬁcant effect of APα which we later discovered.
Neither the inactive stereoisomer 3β-hydroxy-5β-pregnan-20-one
nor progesterone had a signiﬁcant effect upon any of the mor-
phological parameters assessed (Brinton, 1994). In more mature
hippocampal cultures in which structural synaptic connections
had been established, APα protected neurons against picrotoxin-
induced cell death. APα activated chloride ion channels, proved to
be an initial step in the biochemical mechanism underlying both
the retraction and later neurogenesis. Interestingly, 17β-estradiol
a known neurotrophic factor (Brinton, 2009) rapidly reversed the
ﬁlopodial regression induced byAPα indicating that neurosteroids
acting singly and in combination play complex roles in generation
and differentiation of developing neural cells.
Subsequent to the observation of APα-induced neurite regres-
sion of hippocampal neurons in culture, we made the serendip-
itous discovery that APα was increasing mitosis of hippocampal
neurons in culture. We then understood that the APα-induced
regression of neurites was a prelude to APα-induced mitosis. At
the time this discovery was made, understanding of neurogenesis
in brain was limited to embryonic development in the mammalian
brain and regeneration of neurons required for song in the bird
brain. From the vantage point of our current understanding, the
hippocampal neurons undergoing mitosis in the primary hip-
pocampal cell cultures were likely neural progenitor cells. This
early discovery of APα-induced mitosis was supported by bio-
chemical analyses demonstrating that APα induced a signiﬁcant
increase in 3H-thymidine uptake indicating increased DNA syn-
thesis during the S phase of the cell cycle (Wang et al., 2005).
These early foundational studies were followed up with the advent
of an understanding of the neural progenitor pool within the
adult mammalian brain. We determined APα proliferative efﬁ-
cacy in rodent embryonic and adult neural progenitor cells and
embryonic derived human neural progenitor cells. In each of
these cell types, APα induced a signiﬁcant increase in markers
of DNA synthesis, BrdU and 3H-thymidine incorporation,MuLV-
GFP-labeled mitotic neural progenitor cells by FACS analysis and
unbiased quantitative stereology of BrdU-positive cells in both the
subgranular and subventricular proliferative zones (Wang et al.,
2005).
In vitro, the magnitude of APα-induced neurogenesis ranged
from 20 to 30% in the rat hippocampal neural progenitor cells to
37–49% in human cortical neural progenitors (Wang et al., 2005).
The efﬁcacy of APα as a neurogenic factor is comparable to that
induced by bFGF+ heparin. As was the case for cultured embry-
onic hippocampal neurons, APα-induced progenitor cell prolif-
eration was stereoisomer speciﬁc, as 3β-hydroxy-5β-pregnan-20-
one did not increase 3H-thymidine uptake (Wang et al., 2005).
NPC markers nestin and Tuj1 were identiﬁed by immunoﬂuo-
rescence and indicated that the newly formed cells were indeed
neuronal. To determine the mechanism of action induced by
APα in progenitor cells, microarray analysis of cell cycle genes
demonstrated that APα increased the expression of mitotic genes
and inhibited the expression of anti-mitotic genes. APα-induced
proliferation of neural progenitors was antagonized by the both
voltage-gated L-type calcium channel blocker nifedipine indi-
cating a calcium-dependent mechanism for neuroproliferation
(Figure 1; Wang et al., 2005).
Consistent with a calcium-dependent mechanism for neu-
roproliferation, APα induced a rapid increase in intracellu-
lar calcium in hippocampal neurons via a GABAAR-activated
L-type calcium channel (Wang and Brinton, 2008). Following
APα treatment, regulation of intracellular calcium concentration
was measured in E18 rat hippocampal neurons using ratiometric
Fura2-AM imaging. Results indicated that APα rapidly increased
the intracellular calcium concentration in a dose-dependent and
developmentally regulated manner, with an EC50 of 110± 15 nM
and a maximal response occurring at 3 days in vitro. The stereoiso-
mers 3β-hydroxy-5α-hydroxy-pregnan-20-one and 3β-hydroxy-
5β-hydroxy-pregnan-20-one, as well as progesterone, were with-
out signiﬁcant effect. APα-induced intracellular calcium concen-
tration increasewas not observed in calciumdepletedmediumand
was blocked in the presence of the broad spectrum calcium chan-
nel blocker lanthanum ion, or the L-type calcium channel blocker
nifedipine. Furthermore, the GABAAR blockers bicuculline and
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picrotoxin abolished the APα-induced intracellular calcium con-
centration rise (Wang and Brinton, 2008). The in vitro neurogenic
properties of APα coupled with a low molecular weight, easy pen-
etration of the blood brain barrier and lack of toxicity, were key
elements that guided our efforts toward in vivo studies of APα as
a neurogenic regenerative therapeutic with the ambitious aim of
restoring synaptic connections in victims of AD.
ALLOPREGNANOLONE AS A MULTIFACETED
PRO-NEUROGENIC AGENT IN THE TRIPLE-TRANSGENIC AD
MOUSE MODEL
To evaluate APα as a potential therapy for AD it is essential to
obtain preclinical in vivo evidence of APα safety and efﬁcacy.
The triple-transgenic mouse model of Alzheimer’s (3xTgAD), an
AD model is characterized by overexpression of Swedish mutant
APP, mutant P301L Tau in the homozygous mutant of prese-
nilin 1 (M146V) knock-in mouse (Oddo et al., 2003a,b). These
mice have been used extensively as an AD research model as
they age-dependently develop hallmarks that include hippocam-
pal tangle-like pathology, neurological deﬁcits, and intraneuronal
and extraneuronal Aβ deposition. Several completed in vivo stud-
ies have demonstrated the pro-neurogenic and promnesic effects
of APα.We review here three studies from our laboratory in which
a correlation was made between APα-induced neural progenitor
cell survival and improved memory function in 3xTgAD mice
(Wang et al., 2010; Chen et al., 2011; Singh et al., 2011). The basal
concentration of APα in blood plasma (0.47 ng/ml± 0.88) was
signiﬁcantly lower (P < 0.05) than in cortex (10.36 ng/g± 1.43)
FIGURE 2 | Cognitive efficacy of allopregnanolone (APα) prior to
extraneuronal beta-amyloid plaque.Triple-transgenic Alzheimer’s disease
(3xTgAD) mice were exposed to a single dose of APα. Data were plotted as
percent change relative to age-matched vehicle control to assess the
age-related differences in response to APα administered at 3-, 6-, 9-, or
12-months of age. Mice were treated with either APα (subcutaneous,
10mg/kg) or vehicle and 1 h later with bromodeoxyuridine (BrdU)
(intraperitoneal, 100mg/kg). Learning and memory performances were
measured by trace eyeblink conditioning, a hippocampal-dependent task.
Mice were trained by pairing delivery of a tone (conditioned stimulus; CS,
250ms, 2 kHz, 85 dB) as the conditioned stimulus followed by a 250-ms
period of no stimuli, followed by a mild periorbital shock (unconditioned
stimulus; US, 100ms) to elicit an eyeblink response. Mice received two
blocks of 30 trials per day (30–60 s intertrial intervals, 3–4 h interblock
intervals). This behavioral paradigm is subthreshold for inducing neurogenesis
(Wang et al., 2010; Singh et al., 2011). One week following a single dose of
APα, mice were subjected to trace eyeblink conditioning, with 1 day of
habituation and 5 days of paired training. Following paired training, mice were
left undisturbed in their home cages for 9 days and subsequently were tested
for memory. Following the ﬁnal learning trial, BrdU+ cell
survival/hippocampus was measured at the end of the study, 3-weeks
following a single dose of APα and the thymidine analog DNA-synthesis
marker BrdU. Bars represent percent change± sem in response to a single
exposure to APα compared to age-matched vehicle at 3-, 6-, 9-, 12-months of
age in 3xTgAD mice (n ≥7;Wang et al., 2010; Singh et al., 2011). Within
3weeks following a single exposure to APα, neurogenesis, maximal learning,
and memory indicators were increased ∼100% relative to age-matched
vehicle control in adult male 3xTgAD mice when administered at ages prior
to overt AD pathology. The 3xTgAD mouse model displays age-associated
decrements in endogenous neurogenic cell survival in the subgranular zone
(SGZ) as compared with the non-transgenic mice in addition to
age-associated increments in Aβ pathology burden (depicted supra to bar
graph). At 12-months of age, intra- and extraneuronal Aβ 6E10 antibody
staining is apparent and plaque structures are developed in subiculum (Wang
et al., 2010; Singh et al., 2011). The therapeutic response to APα was speciﬁc
to the transgenic AD phenotype, as the age-matched non-transgenic mice
did not beneﬁt from a single exposure to APα. Remarkably, a single exposure
to APα increased neurogenesis and subsequent cell survival in aged
non-transgenic mice when administered at 15-months of age (non-Tg data
not in ﬁgure; Singh et al., 2011). At 12-months of age, the point when
extraneuronal plaques are known to be present in this AD mouse model, a
single exposure to APα was ineffective. At ages prior to extraneuronal Aβ
plaques, APα signiﬁcantly (P <0.05) increased BrdU+ cell survival, maximal
learning, and memory function relative to age-matched vehicle control.
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FIGURE 3 | Optimal allopregnanolone therapeutic regimen.
Triple-transgenic Alzheimer’s disease (3xTgAD) mice were treated
subcutaneously with allopregnanolone (APα; 10mg/kg) once per month
(1/month), once per week (4/month), or every other day (12/month) to
determine extent of neurogenesis (depicted by red colored arrow) and
pathology reduction capacity (depicted by black colored arrow) on double
y -axes (Chen et al., 2011). The dosing frequency determined the therapeutic
efﬁcacy for both neurogenic and pathological endpoints. All three APα
treatments were initiated when 3xTgAD mice reached 3months of age.
Upon completion of each treatment paradigm, BrdU+ labeled nuclei were
counted to assess neurogenesis. Both the 1/month APα treatment and the
4/month APα treatment induced a signiﬁcant increase in neurogenesis,
with the latter regimen yielding the greater increase in neurogenesis.
However, the 3/week/3months (12/month) treatment induced a signiﬁcant
decrease in neurogenesis. Brain sections from 3xTgAD mice treated with
APα or vehicle were immunostained. Aβ immunoreactivity was detected
and indicated that the 1/week/6months (4/month) APα treatment
signiﬁcantly decreased Aβ immunoreactivity. Efﬁcacy of Aβ reduction in
4/month was comparable to the 12/month APα treatment whereas the
1/month APα treatment was ineffective at reducing Aβ immunoreactivity
(Chen et al., 2011). From these dosing frequency studies, we conclude that
the optimal treatment regimen for AD is to intervene as early as possible
with once per week administration of APα to simultaneously promote
neurogenesis and subsequent cell survival.
in young adult male non-transgenic (non-Tg) mice, indicat-
ing a higher brain accumulation, consistent with locally syn-
thesized APα in hippocampus and cortex. In contrast, 3xTgAD
mice exhibited a lower basal level of APα in the cerebral cor-
tex (3xTgAD, 6.49 ng/g± 2.02 versus non-Tg, 10.36 ng/g± 1.43),
suggesting either impairment of APα synthesis or accelerated APα
metabolism in 3xTgAD mice brain (Wang et al., 2010). A decline
in neurogenesis occurs within the SGZ and SVZ in male and
female 3xTgAD mice in correlation with AD pathology (Brinton
and Wang, 2006; Rodriguez et al., 2008, 2009; Wang et al., 2010).
APα promoted neurogenesis in the hippocampal SGZ to reverse
learning and memory deﬁcits. Neural progenitor cell proliferation
and subsequent cell survival was determined by analysis of BrdU
incorporation. We veriﬁed the phenotype of in vivo newly formed
BrdU+ cells by triple-immunolabeling coronal sections of mouse
hippocampi adjacent to those that were stereologically analyzed
and derived from 3-month-old 3xTgAD mice treated with a sin-
gle subcutaneous injection of 10mg/kg APα (Wang et al., 2010).
The phenotypic markers assessed were doublecortin DCX, to label
young immature neurons; NeuN, to label mature neurons; and
glial ﬁbrillary acidic protein (GFAP), to label astrocytes. Confocal
microscopy identiﬁed BrdU-positive cells colocalized with DCX
alone or together with NeuN. Newly born cell survival was further
conﬁrmed by immunolabeling coronal sections derived from APα
(subcutaneous, 10mg/kg)-treated 3xTgAD mouse dentate gyrus
22 days post-APα treatment and post-behavioral analyses. BrdU+
cells were located deep within the granular cell layer, indicating
the migration of newly formed cells from the SGZ to the granule
cell layer (Wang et al., 2010). Collectively, these data indicated that
newly formed cells, generated following APα treatment, express a
neuronal phenotype.
Learning and memory function was assessed using the
hippocampal-dependent trace eyeblink conditioning paradigm.
At 3months of age, the basal level of BrdU+ cells in the SGZ of
3xTgAD mice was signiﬁcantly lower relative to non-transgenic
(non-Tg) mice, despite the lack of evident AD pathology (Wang
et al.,2010).APα signiﬁcantly increased, in adose-dependentman-
ner, BrdU+ cells in the SGZ of 3xTgAD mice and restored SGZ
proliferation to normal magnitude of non-Tg mice (Wang et al.,
2010). Coinciding with deﬁcits in adult neural progenitor prolif-
eration, 3xTgAD mice exhibited deﬁcits in learning and memory.
APα reversed the cognitive deﬁcits to restore learning and mem-
ory performance to the level of normal non-Tg mice (Wang et al.,
2010). In 3-month-old 3xTgAD mice,APα increased proliferation
and promoted the survival of newly born hippocampal dentate
granule cells (Wang et al., 2010). Neural progenitor cell numbers
signiﬁcantly correlated with APα-induced memory performance.
Interestingly, the early deﬁcits in neurogenesis detected in this
genetic model of AD were evident prior to immunodetectable
β-amyloid (Aβ).
To broaden this preclinical discovery work, studies were
extended to 3xTgAD mice aged 6-, 9-, 12-months, therapeutically
relevant to early and mid-stage AD. Comparable to the 3-month
mice, APα increased proliferative activity, promoted the survival
of newly born hippocampal dentate granule cells, and restored
cognition affected by AD pathology in 6-, 9-month-old 3xTgAD
mice while having no signiﬁcant impact on their age-matched
normal non-Tg counterparts (Singh et al., 2011). BrdU+ neural
progenitor cell survival was assessed after 3 weeks, following a
single exposure to APα (10mg/kg). During the 3-week period,
a hippocampal-dependent associative learning and memory task
was performed which evidently allowed granule cells sufﬁcient
time to proliferate and migrate at the border between the hilus
and the granule cell layer subsequent to their incorporation into
the existing neural network. APα signiﬁcantly increased survival
of BrdU+ cells and recovered hippocampal-dependent cognition
in 6-, and 9-month-old 3xTgAD mice, in the presence of intraneu-
ronal Aβ, whereas APα was ineffective subsequent to development
of extraneuronal Aβ plaques in 12-month-old mice. Surprisingly,
cognition was restored to maximum by the ﬁrst day of trace eye-
blink conditioning, only 1week following a single exposure to
APα. Hippocampal-dependent associative learning accomplished
by repeated trials of an auditory tone followed by a mildly aver-
sive shock stimulus,was sustained throughout behavioral training.
Learning and memory function in APα-treated 3xTgAD mice
was 100% greater in magnitude compared to the age-matched
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vehicle-treated group (Figure 2) and was remarkably comparable
to themaximal normal non-Tgmouse performance. Furthermore,
we observed an upward trend albeit not statistically signiﬁcant,
toward efﬁcacy in non-Tg at 12months of age. The behavioral
experiment was then extended to include 15-month-old non-Tg
mice to determine whether or not APα presented a therapeutic
beneﬁt to older non-AD mice that may have a greater degree of
age-related diminution of neurogenic growth factors. Our results
indicated that hippocampal BrdU+ cell survival was signiﬁcantly
increased by a single exposure to APα and cognitive performance
was signiﬁcantly enhanced in 15-month-old male non-Tg mice
(Singh et al., 2011). In normal non-AD men as early as age 40,
a decline in APα has been reported (Genazzani et al., 1998). The
therapeutic beneﬁt found in aged non-Tg mice suggests that at
least in males, APα therapy could supplement an age- and gender-
related decline in this neurogenic factor. These ﬁndings provided
preclinical evidence of APα-promoted survival of newly generated
cells and paralleled restoration of cognitive performance in the
pre-plaque phase of AD pathology and in late-stage normal aging.
To further advance efforts to assess the preclinical efﬁcacy of
APα for AD, our group designed long-term studies. The stud-
ies were designed to test APα using the same age of enrollment
(3xTgAD male 3months of age; prior to overt intraneuronal
Aβ), neurogenically efﬁcacious dose of 10mg/kg via subcutaneous
route of administration, matching our previous studies. In addi-
tion to neurogenic efﬁcacy, the long-term studies were extended to
determine the disease modifying effects afforded by the therapeu-
tic regimen. Speciﬁcally, Chen et al. (2011) tested three treatment
regimens – once per month, once per week, and every other day
(Figure 3). Based on measured endpoints of Aβ oligomers by
immunostain and immunoblot approaches, the every other day
treatment regimen was maximally efﬁcacious but did not increase
neurogenesis. The once per month APα treatment was efﬁcacious
for proliferation of neural progenitor cells in the SGZ (and SVZ,
unpublished) but not for decreased Aβ pathology. The once per
month treatment regimen (Chen et al., 2011) was similar to the
single exposure treatment paradigm that improved learning and
memory performance after a single exposure (Singh et al., 2011).
Analyses to determine the optimal treatment paradigm indicated
that APα administered once per week for 6months was maximally
efﬁcacious for both neurogenic and anti-amyloidogenic endpoints
(Figure 3). In parallel to the 3-month-old mice administered once
per week APα, we simultaneously began treatment of a 6-month-
old male 3xTgAD group. When APα was administered beginning
at 6months of age, the age at which intraneuronal plaques are
apparent in this mouse model, the appearance of Aβ pathology
paralleled cessation of APα efﬁcacy. Once intraneuronal Aβ is
extracellularly localized, the efﬁcacy of APα is largely diminished.
This suggested to us that intraneuronalAβ accumulation is a deter-
mining factor that focuses the window of APα therapeutic efﬁcacy
on the early stages of AD.
There is a well-established relationship between cholesterol
homeostasis and Aβ generation. Increasing evidence indicates
that altered cholesterol metabolism is linked to AD pathology
(Schumacher et al., 2004; Mellon et al., 2008). In addition to the
mechanism of action whereby APα induces neurogenesis through
excitation of GABAAR chloride channels in neural progenitor cells
(Figure 1; Wang et al., 2005, 2008, 2010; Brinton and Wang, 2006;
Wang and Brinton, 2008), APα regulates cholesterol homeostasis
via the Liver-X-receptor (LXR) and pregnane-X-receptor (PXR)
system (Chen et al., 2011). LXR, a nuclear hormone receptor
abundant in the brain (Whitney et al., 2002), acts as a molecu-
lar sensor of cholesterol levels and initiates cholesterol clearance
(Whitney et al., 2002). LXR activation increases cholesterol efﬂux
through up-regulating ABCA1 and ApoE expression, and pre-
vents the hyper-activation of γ-secretase and over-production of
Aβ (Whitney et al., 2002; Shenoy et al., 2004; Jiang et al., 2008).
LXR activation has been demonstrated to improve cognitive func-
tion in multiple mouse models of amyloidogenesis (Schultz et al.,
2000; Whitney et al., 2002; Yang et al., 2006; Xiong et al., 2008;
Donkin et al., 2010; Leduc et al., 2010). Importantly, LXR lig-
ands have been shown to activate pregnane-X-receptor (PXR;
Riddell et al., 2007). Results from our analyses indicated that
in parallel with an APα-induced increase in LXR expression in
the pre-pathology condition, APα also increased PXR expression
in the pre-pathology 3xTgAD mouse brain (Chen et al., 2011).
PXR activation induces cytochrome P450 3A (CYP3A) enzymes
includingCYP3A4 andCYP3A13 and leads to cholesterol hydroxy-
lation and activation of organic anion transporters for cholesterol
extrusion (Sun et al., 2003). In addition to increased LXR and
PXR expression, APα treatment initiated in pre-Aβ pathology
3-month-old 3xTgAD mice treated once per week for 6months
displayed increased expression of 3-hydroxy-3-methyl-glutaryl-
CoA-reductase (HMG-CoA-R; Chen et al., 2011). The increase in
HMG-CoA-R is at ﬁrst paradoxical as it is the rate-limiting enzyme
in cholesterol synthesis. HMG-CoA reductase is also required
for oxysterol generation which activate LXR and PXR-mediated
gene transcription for cholesterol and lipid transport proteins
(Leduc et al., 2010). Thus, the APα-induced increase in brain LXR
and PXR leads to increased cholesterol efﬂux, thereby reducing
γ-secretase activation by cholesterol-laden lipid rafts. Increased
cholesterol efﬂux provides a plausible mechanism to explain how
APα decreased the generation of both 27 and 56 kDa intraneu-
ronal Aβ oligomers after 6months of once per week treatment
(Chen et al., 2011).
Our ﬁndings suggest that in vivo, brain cholesterol homeostasis
and intraneuronal Aβ are tightly coupled with APα efﬁcacy (Chen
et al., 2011). Deposition of Aβ in the extracellular compartment
disconnected this coupled pathway and led to a loss of APα efﬁcacy
in advanced stages of AD-like pathology in the 3xTgAD model.
APα signiﬁcantly reduced Aβ generation in hippocampus, cor-
tex, and amygdala, which was paralleled by decreased mitochon-
drial Aβ-binding alcohol dehydrogenase (ABAD) and reduced
microglia activation assessed as reduced expressionof OX42 (Chen
et al., 2011). APα has also been shown to increasemyelin basic pro-
tein in organotypic slice cultures of rat cerebellum (Schumacher
et al., 2004) and delay demyelination in Niemann–Pick C mice
(Mellon et al., 2008). APα may stimulate oligodendrocyte prog-
enitor cells in addition to neural progenitor cells. In oligodendro-
cytes, the myelin marker CNPase was increased by once per week
APα, indicating pro-myelinating capabilities in this mouse model
(Chen et al., 2011). Collectively, APα is a multifaceted neuros-
teroid that promotes neurogenesis while simultaneously reducing
AD pathology in the 3xTgAD mouse model.
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TRANSLATION OF PRECLINICAL ALLOPREGNANOLONE
STUDIES TO CLINICAL ALZHEIMER’S DISEASE THERAPY
Currently there are no effective treatments to delay progres-
sion of Alzheimer’s, halt the degenerative process or effectively
treat the disease. In fact, since 2003, there have been no new
drug approvals for AD by the United States Food and Drug
Administration (FDA). Of the ﬁve FDA-approved AD drugs, four
are cholinesterase inhibitors and memantine is an N -methyl-d-
aspartate (NMDA) receptor antagonist. As part of the recent AD
Neuroimaging Initiative or “ADNI”, mild cognitive impairment
patients who received cholinesterase inhibitors with or with-
out memantine were more functionally impaired, showed greater
decline in scores, and progressed to dementia sooner than patients
who did not receive treatment (Schneider et al., 2011). Phase 3
clinical trials have failed to therapeutically modify AD via the inhi-
bition of amyloid cascade targets including a gamma-secretase
modulator (tarenﬂurbil), gamma-secretase inhibitor (semagace-
stat), and beta-secretase inhibitor (tramiprosate; Karran et al.,
2011). Most AD researchers agree that it is ineffective to eval-
uate therapeutic efﬁcacy in people that have reached the later
stages of AD, when irreversible damage has occurred. To mod-
ify disease progression, therapies need to be instituted early to
target speciﬁc physiological stages of AD progression. One strat-
egy to detect dysfunction of the neuroendocrine system would
be to access blood levels of APα in persons at risk for AD. Pre-
clinical biomarkers to predict clinical therapeutic potential and
clinical biomarkers that conﬁrm target engagement anddose selec-
tion are needed as prognostic and diagnostic tools for AD disease
progression to select and track treatment strategies relevant to
each pathological stage of dementia (Buckholtz, 2011). Currently,
large-scale multicenter controlled studies are being conducted
in US, Europe, Japan, and Australia (ADNI) to systematically
develop and validate candidate biomarkers such as cerebrospinal
ﬂuid proteins and structural and functional imaging signatures
(Hampel et al., 2008). Ideally, complementary brain imaging
and ﬂuid biomarkers will be developed for clinical evaluation
of AD.
As an endogenousmetabolite of progesterone,men andwomen
are exposed to APα throughout their lifetime. During repro-
ductive years, women are chronically exposed to APα concen-
trations ranging from less than 1 nmol/l (0.32 ng/ml) to over
4 nmol/l (1.27 ng/ml) during the luteal phase (Genazzani et al.,
1998). During pregnancy, blood production rate of APα can
reach 100mg/24 h (Dombroski et al., 1997) and remain high
throughout the third trimester of pregnancy at levels up to
157 nmol/l (50 ng/ml), which while associated with drowsiness,
is not associated with adverse effects for either mother or fetus
(Luisi et al., 2000). In response to acute stress, the fetal brain
can increase synthesis of APα de novo independent of maternal
supply and of the hypothalamic–pituitary–adrenal axis (Nguyen
et al., 2003). Women receiving progesterone therapy can gener-
ate between 0.9 nmol/l (0.3 ng/ml) and 4.2 nmol/l (1.3 ng/ml) of
APα, consistent with levels generated during the menstrual cycle.
Analyses following a single intramuscular injection of 200mg
progesterone (APα precursor) indicated similar proﬁles in men
and women with peak levels of APα of 35 nmol/l (11 ng/ml) for
men and 41 nmol/l (13 ng/ml) for women in the ﬁrst hours after
administration (Soderpalm et al., 2004). Post-mortem human
brain tissue from women revealed APα levels in the range of
14–21 ng/g (Bixo et al., 1997). Oral delivery of APα would be
convenient and readily tolerated however this route presents a
challenge because of the low solubility properties of APα and
ﬁrst-pass metabolism in the digestive tract and liver. Results of
our preclinical analyses predict that the optimal therapeutic APα
regimen will be a once per week transdermal or subcutaneous
administration (Figure 3). Initial pharmacokinetic analyses of
a topically applied formulation of APα in rabbit, indicated that
APα is absorbed transdermally to reach the blood circulation
with accumulation in the brain that is relatively slowly elimi-
nated when compared to intravenous dosing (Table 1). Safety
is most critical for translational studies. In the past decade,
several clinical studies by Bäckström’s group at Umeå Univer-
sity, Sweden have demonstrated that APα is safe with short-
lived, mild self-reported sedation (drowsiness). Following dos-
ing of APα 0.09mg/kg (three cumulative doses of 0.015, 0.03,
0.045mg/kg within 1 h) fully bioavailable intravenous adminis-
tration, van Broekhoven et al. (2007) measured maximum blood
levels of 150 nmol/l (48 ng/ml) in men and 100 nmol/l (32 ng/ml)
in women (Table 1). Interestingly, mean levels of APα were found
to be higher in men compared to women at baseline (men,
2.4 nmol/l or 0.76 ng/ml versus women, 0.4 nmol/l or 0.13 ng/ml)
and after each of three doses of intravenous APα. Volume of
distribution, elimination half-life, and the area under the curve
(AUC) adjusted for body weight did not differ between men and
women in the clinical study (van Broekhoven et al., 2007). To
date, APα has not been studied in clinical trials for the treatment
of AD.
Human, as well as rodent, brains exhibit a signiﬁcant and
profound reduction in the proliferative pool and regenerative
potential of neural stem cells as they age, a phenomenon that
may be exacerbated in prodromal and mild AD brains. Both the
pool of neural stem cells and their proliferative potential are com-
promised in the course of AD (Lazarov et al., 2010; Winner et al.,
2011). In parallel, APα content, along with a host of other factors,
is diminished in the brains of AD patients compared to age-
matched controls (Weill-Engerer et al., 2002; Marx et al., 2006;
Naylor et al., 2010). While de novo synthesis of APα in brain is
diminished, peripheral delivery could restore levels to normal. A
deﬁcient milieu of endogenous neurosteroids and depleted neu-
rogenesis demonstrate the therapeutic need for APα in the human
brain. Promnesic effects are not achievable with every APα dosing
regimen or intervention point. Decrements in learning and mem-
ory have been reported in animals and humans although these
studies are either acute measures of memory performance within
minutes of a sedative dose (Kask et al., 2008) or chronic treatment
paradigms that mimic stress conditions (Turkmen et al., 2006).
When high doses or chronic treatment regimens are employed,
APα acts similar to benzodiazepines to reduce learning and impair
memory. APα administered twice daily at high doses to male rats
for several consecutive days decreased performance on the Mor-
ris water maze, escape latency, path length, and thigmotaxis and
it was determined that pretreatment induced a partial tolerance
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against acute APα effects (Turkmen et al., 2006). It is important to
consider that GABAergic synapses are not universally inﬂuenced
by APα and that many factors including GABAAR subunit com-
position and receptor density inﬂuence the local cellular response.
Thus for therapeutic use of APα, it is imperative to determine
the proper dosing regimen which may be speciﬁc to each indica-
tion. Aside from AD, the proper APα dosing regimen has shown
therapeutic potential in research models of several brain disorders
or injuries including catamenial epilepsy (Reddy and Rogawski,
2001; Rogawski, 2003), spontaneous seizures (Concas et al., 1996),
diabetic neuropathy (Leonelli et al., 2007), Niemann–Pick type
C neurodegenerative disorder (Grifﬁn et al., 2004; Ahmad et al.,
2005), and traumatic brain injury (He et al., 2004a,b;Djebaili et al.,
2005).APα is absorbed bymultiple routes of administration,pene-
trates the blood brain barrier well, exhibits a wide margin of safety
particularly when given transdermally or subcutaneously and for
the 3xTgAD mouse model is most efﬁcacious when administered
only once per week which also contributes to its margin of safety
(Table 1). Importantly, APα is a small molecular weight, blood
brain barrier penetrant molecule with safety data in animals and
humans (Timby et al., 2006; van Broekhoven et al., 2007; Grant
et al., 2008;Kask et al., 2008,2009;Wang et al., 2010). Toour knowl-
edge, APα is the only small molecule agent that both promotes
regenerative function in the brain and simultaneously reduces AD
pathology burden.
CONCLUSION
Herein we reviewed preclinical evidence for APα-induced pro-
motion of neurogenesis (Wang et al., 2005, 2010), recovery of
learning and memory function (Wang et al., 2010; Singh et al.,
2011), and reduction of AD pathology burden (Chen et al., 2011)
in the 3xTgAD mouse model. Moreover, APα induction of cell
cycle gene expression (Wang et al., 2005) and key regulators of
cholesterol homeostasis (Chen et al., 2011) provide mechanistic
plausibility for its therapeutic efﬁcacy to promote neurogenesis
and cognitive function while reducing AD pathology. Our data
show that regeneration is achieved with either once per month
or once per week regimen of APα. Reduction of AD pathology
can be achieved with once per week or every other day regimens.
The combination of regeneration and reduction of pathology
was achievable with the once per week APα treatment regimen.
Together with the dosing frequency, the magnitude of pathology
at the start of treatment intervention is critical to therapeutic
efﬁcacy. Administration of APα prior to and during the early
stages of AD pathology signiﬁcantly increased the regenerative
response in brain while also reducing burden of pathology in an
AD mouse model. APα treatment initiated at the point of Aβ
plaque generation was not efﬁcacious indicating that APα targets
regenerative and pathology-reducing mechanisms present during
the early to mid-stages of the disease. Based on the therapeutic
efﬁcacy of APα in a preclinical AD mouse model and in normal
aged mice, we predict that APα has potential therapeutic bene-
ﬁt in humans to delay progression in persons with familial early
onset AD and to prevent and delay disease in late onset AD. In
these populations, APα could be an effective therapy to promote
the regenerative potential and myelination capacity of the brain
to prevent or delay progression of mild cognitive impairment to
www.frontiersin.org January 2012 | Volume 2 | Article 117 | 11
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clinically diagnosed AD. In summary, targeting a unique mecha-
nism of action,APα promotes the innate regenerative capability of
the brainby increasing thenumber and survival of newly generated
neurons.
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